Roth Capital Reiterates Buy on Concert Pharma (CNCE) Following a Milestone Achievement
Tweet Send to a Friend
Roth Capital reiterated a Buy rating and $32.00 price target on Concert Pharmaceuticals (NASDAQ: CNCE) after the company achieved its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
